Compare LUCD & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUCD | PLX |
|---|---|---|
| Founded | 2018 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.9M | 207.1M |
| IPO Year | 2021 | 1996 |
| Metric | LUCD | PLX |
|---|---|---|
| Price | $0.40 | $2.89 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | $4.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 7.8M | 940.5K |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | N/A | ★ 0.31 |
| Revenue | $4,346,000.00 | ★ $52,744,000.00 |
| Revenue This Year | $34.40 | $65.42 |
| Revenue Next Year | $191.30 | N/A |
| P/E Ratio | ★ N/A | $9.77 |
| Revenue Growth | ★ 79.00 | N/A |
| 52 Week Low | $0.30 | $1.65 |
| 52 Week High | $1.63 | $3.19 |
| Indicator | LUCD | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 39.70 | 55.28 |
| Support Level | $0.30 | $2.54 |
| Resistance Level | $0.48 | $3.19 |
| Average True Range (ATR) | 0.04 | 0.18 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 8.03 | 60.14 |
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.